What really separates roflumilast (Zoryve) from other PDE4 inhibitors — and why does it matter for your patients with atopic dermatitis, psoriasis, or seborrheic dermatitis? In this episode, Dr. Ted Lane sits down with Dr. Chris Bunick, Associate Professor of Dermatology at Yale School of Medicine and Editor-in-Chief of Dermatology Times, for a deep dive into the biochemistry, formulation science, and clinical implications behind this breakthrough topical treatment.
In this episode, you'll learn:
Whether you're a dermatologist, resident, PA, NP, or skincare enthusiast who wants to understand the why behind cutting-edge topicals, this episode is packed with clinical and scientific insight you won't find anywhere else.
๐๏ธ This episode is sponsored by Arcutis Biotherapeutics, maker of roflumilast cream and foam.
๐ง Send your questions to: questions@scienceofskinnsummit.com
๐ Science of Skin Summit — September 19–21, Austin, TX
๐ Longevity Meeting — February 19 - 21, Scottsdale, AZ
Subscribe, leave a 5-star review, and follow Dr. Bunick's podcast: ABCDs in Dermatology.
Disclaimer: This podcast is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment.

Roflumilast Cream for Toddler Eczema, Psoriasis & Seborrheic Dermatitis
21:56

Hair Loss Treatments: Dr. Nicole Rogers on What Actually Works
32:57

Clinical Trials in Dermatology: Insider Tips from Top Researchers
28:32